AFP and hepatocellular carcinoma: A subgroup analysis of the phase III randomized controlled trial LEAP 002 (10) revealed that patients with macrovascular invasion/extrahepatic metastasis, hepatitis B virus (HBV)-related HCC, and alpha-fetoprotein (AFP) levels >400 ng/mL benefited more from pembrolizumab combined with lenvatinib than from lenvatinib alone.